Vodis Pharmaceuticals Inc. (CSE:VP,FSE:1JV1) (” Vodis ” or the ” Company “) is pleased to announce it has been notified by its tenant grower, Our Church International LLC (“OCI”), they have begun to sell marijuana product carrying the Vodis brand in Washington State.
This follows the February 23, 2017 announcement regarding OCI and Vodis’s wholly owned subsidiary, Vodis USA, Inc. (“Vodis USA”), having entered into a Product Licensing and Marketing Agreement (the “Licensing Agreement”). The Licensing Agreement allows the Vodis name, images, and Vodis-inspired designs and concepts to be used to brand, market, and sell marijuana products across Washington State.
Vodis CEO, Ivan Miliovski states: “This is yet another major milestone for the company. We have worked hard with the OCI team to ensure the Vodis brand is associated with the highest quality product OCI has to offer. With Vodis-developed marketing strategies, we expect the Vodis brand will be broadly recognized by consumers and investors, and will become synonymous with quality across, and eventually beyond, Washington State.”
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the US and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.
Ivan Miliovski, CEO
Vodis Pharmaceuticals Inc.
For further information please contact:
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward- looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the use of proceeds of this financing. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.
The Canadian Securities Exchange has neither approved nor disapproved the contents
of this news release and accepts no responsibility for the adequacy or accuracy hereof.